{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:00:55Z","timestamp":1787018455638,"version":"build-2736575974"},"reference-count":20,"publisher":"American Psychiatric Association Publishing","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[2002,11,1]]},"DOI":"10.1176\/appi.ajp.159.11.1869","type":"journal-article","created":{"date-parts":[[2002,10,31]],"date-time":"2002-10-31T18:05:49Z","timestamp":1036087549000},"page":"1869-1875","source":"Crossref","is-referenced-by-count":126,"title":["Transdermal Selegiline in Major Depression: A Double-Blind, Placebo-Controlled, Parallel-Group Study in Outpatients"],"prefix":"10.1176","volume":"159","author":[{"given":"J. Alexander","family":"Bodkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay D.","family":"Amsterdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"R15911BAJGECDD","doi-asserted-by":"crossref","unstructured":"Himmelhoch JM, Thase ME, Mallinger AG, Houke P: Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148:910-916","DOI":"10.1176\/ajp.148.7.910"},{"key":"atypb2","doi-asserted-by":"crossref","unstructured":"Nolen WA, Haffmans J: Treatment of resistant depression: review on the efficacy of various biological treatments, specifically in major depression resistant to cyclic antidepressants. Int Clin Psychopharmacol 1989; 4:217-228","DOI":"10.1097\/00004850-198907000-00004"},{"key":"R15911BAJDAGGH","doi-asserted-by":"crossref","unstructured":"Bodkin JA, Kwon AE: Selegiline and other atypical MAO inhibitors in depression. Ann Psychiatry 2001; 31:385-391","DOI":"10.3928\/0048-5713-20010601-08"},{"key":"R15911BAJBBFJH","doi-asserted-by":"crossref","unstructured":"Shih JC, Chen K, Ridd MJ: Monoamine oxidase: from genes to behavior. Ann Rev Neurosci 1999; 22:197-217","DOI":"10.1146\/annurev.neuro.22.1.197"},{"key":"R15911BAJBFDCF","doi-asserted-by":"crossref","unstructured":"Youdim MBH: The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction. Acta Psychiatr Scand Suppl 1995; 386:5-7","DOI":"10.1111\/j.1600-0447.1995.tb05917.x"},{"key":"R15911BAJJCHAA","doi-asserted-by":"crossref","unstructured":"Mann JJ, Aarons SF, Wilner PJ, Keilp JG, Sweeney JA, Pearlstein T, Frances AJ, Kocsis JH, Brown RP: A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. Arch Gen Psychiatry 1989; 46:45-50","DOI":"10.1001\/archpsyc.1989.01810010047007"},{"key":"atypb3","unstructured":"McGrath PJ, Stewart JW, Harrison W, Wager S, Nunes EN, Quitkin FM: A placebo-controlled trial of\n                      L\n                      -deprenyl in atypical depression. Psychopharmacol Bull 1989; 25:63-67"},{"key":"R15911BAJFIIHJ","doi-asserted-by":"crossref","unstructured":"Sunderland T, Cohen RM, Molchan S, Lawlor BA, Mellow AM, Newhouse PA, Tariot PN, Mueller EA, Murphy DL: High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry 1994; 51:607-614","DOI":"10.1001\/archpsyc.1994.03950080019003"},{"key":"R15911BAJJJCEF","doi-asserted-by":"crossref","unstructured":"McGrath PJ, Stewart JW, Quitkin FM: A possible\n                      L\n                      -deprenyl induced hypertensive reaction. J Clin Psychopharmacol 1989; 9:310-311","DOI":"10.1097\/00004714-198908000-00024"},{"key":"R15911BAJBIDJE","doi-asserted-by":"crossref","unstructured":"Sunderland T, Mueller EA, Cohen RM, Jimerson DC, Pickar D, Murphy DL: Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology (Berl) 1985; 86:432-437","DOI":"10.1007\/BF00427904"},{"key":"R15911BAJEFGFB","doi-asserted-by":"crossref","unstructured":"Lipper S, Murphy DL, Slater S, Buchsbaum MS: Comparative behavioral effects of clorgyline and pargyline in man: preliminary evaluation. Psychopharmacology (Berl) 1979; 62:123-128","DOI":"10.1007\/BF00427124"},{"key":"R15911BAJIDBEB","doi-asserted-by":"crossref","unstructured":"Barrett JS, Hochadel TJ, Morale RJ, Rohatagi S, DeWitt KE, Watson SK, Darnow J, Azzaro AJ, DiSanto AR: Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males. J Clin Pharmacol 1997; 37:238-247","DOI":"10.1002\/j.1552-4604.1997.tb04786.x"},{"key":"R15911BAJIJGBB","unstructured":"VanDenBerg CM, Azzaro AJ, Blob LF, Kemper EM, Sharoky M: Does the selegiline transdermal system (STS) require a dietary tyramine restriction? (abstract). J Clin Pharmacol 2001; 14:1031"},{"key":"R15911BAJFBGHF","doi-asserted-by":"crossref","unstructured":"Rohatagi S, Barrett JS, DeWitt KE, Morales RJ: Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. Biopharm Drug Dispos 1997; 18:567-584","DOI":"10.1002\/(SICI)1099-081X(199710)18:7<567::AID-BDD49>3.0.CO;2-7"},{"key":"R15911BAJJDAJH","doi-asserted-by":"crossref","unstructured":"Knoll J: Deprenyl (selegiline): the history of its development and pharmacologic action. Acta Neurol Scand Suppl 1983; 95:57-80","DOI":"10.1111\/j.1600-0404.1983.tb01517.x"},{"key":"R15911BAJGGGGI","doi-asserted-by":"crossref","unstructured":"Gourlay SG, Forbes A, Marriner T, McNeil JJ: Predictors and timing of adverse experiences during transdermal nicotine therapy. Drug Saf 1999; 20:545-555","DOI":"10.2165\/00002018-199920060-00007"},{"key":"R15911BAJIFJAI","doi-asserted-by":"crossref","unstructured":"Vaillant L, Biette S, Machet L, Constans T, Monpere C: Skin acceptance of transcutaneous nitroglycerin patches: a prospective study of 33 patients. Contact Dermatitis 1990; 23:142-145","DOI":"10.1111\/j.1600-0536.1990.tb04774.x"},{"key":"R15911BAJHHJIC","doi-asserted-by":"crossref","unstructured":"Thompson C, Peveler RC, Stephenson D, McKendrick J: Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: a randomized comparison of fluoxetine and a tricyclic antidepressant. Am J Psychiatry 2000; 157:338-343","DOI":"10.1176\/appi.ajp.157.3.338"},{"key":"R15911BAJFHEGH","doi-asserted-by":"crossref","unstructured":"DiMatteo MR, Lepper HS, Crogan TW: Depression as a risk factor for noncompliance with medical treatment. Arch Intern Med 2000; 160:2101-2107","DOI":"10.1001\/archinte.160.14.2101"},{"key":"R15911BAJECEIJ","doi-asserted-by":"crossref","unstructured":"Guelfi JD, Strub N, Loft H: Efficacy of intravenous citalopram compared with oral citalopram for severe depression: safety and efficacy data from a double-blind, double-dummy trial. J Affect Disord 2000; 58:201-209","DOI":"10.1016\/S0165-0327(99)00120-2"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.159.11.1869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T21:49:42Z","timestamp":1722376182000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.159.11.1869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11,1]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2002,11,1]]}},"alternative-id":["10.1176\/appi.ajp.159.11.1869"],"URL":"https:\/\/doi.org\/10.1176\/appi.ajp.159.11.1869","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,11,1]]}}}